Exhibit 99.1
 |
NASDAQ: INM
Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com |
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
| · | Completed enrollment in Phase 2 Clinical Trial; data readout expected during calendar 3Q 2023 | |
| · | 120% quarter-over-quarter revenue growth in the commercial BayMedica subsidiary | |
| · | Published a peer-reviewed study showing the anti-inflammatory potential of rare cannabinoids |
Vancouver, BC – May 15, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the third quarter of the fiscal year 2023 (“FY 3Q23”) which ended March 31, 2023.
The Company’s full financial statements and related MD&A for the third quarter ended March 31, 2023, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
“The third quarter of fiscal year 2023 was an important period for InMed, as we achieved several key milestones across our different business segments, including completing enrollment in our Phase 2 clinical trial for epidermolysis bullosa, marking the first time cannabinol (“CBN”) has completed a Phase 2 clinical trial. We look forward to the data read out during 3Q and will then be in a better position to evaluate our strategic opportunities for the program.” said Eric A. Adams, President and CEO of InMed. “We are increasingly excited about the data we are seeing in our preclinical ocular and neurodegenerative disease programs where we are researching proprietary cannabinoid analogs in the treatment of various indications.”
“We also hit another significant milestone in our commercial BayMedica subsidiary, surpassing $1M in quarterly revenues for the first time from the sales of rare cannabinoids to the Health and Wellness (“H&W”) sector, representing a 120% increase over 2Q sales.” Adams continued, “In the last few months we have seen a noticeable increase in awareness, understanding and adoption of rare cannabinoids in the H&W sector, evidenced by leading companies expanding their product lines to include new formats and formulations using rare cannabinoids such as the non-psychoactive ingredient cannabichromene (“CBC”). We are encouraged by two consecutive periods of significant quarter over quarter revenue growth. We will continue to support growth in a fiscally prudent manner in this relatively nascent market, where product demand can be unpredictable. The combination of a pharmaceutical drug development pipeline, together with a revenue generating commercial operation that will be contributing to extending our cash runway makes InMed a unique company within the rare cannabinoid space.”
Business update
Pharmaceutical Development Programs
INM-755 – Phase 2 Clinical Trial in EB
In March 2023, the Company concluded enrollment of 19 patients in its Phase 2 clinical trial, with the last patient completing treatment in April, using the investigational drug INM-755 CBN cream for the treatment of symptoms in persons with epidermolysis bullosa (“EB”), a rare genetic skin disease. The study used a within-patient, double-blind design in which matched index areas were randomized to INM-755 (cannabinol) cream or vehicle cream as a control. Selected matched index areas may have been wounds or non-wound areas. In this study, designed to measure safety and obtain preliminary evidence of efficacy, there is no single primary efficacy endpoint. Net benefit from INM-755 cream will be evaluated within each patient and based on their clinical needs at baseline. Based on their presenting symptoms, the majority of the enrolled and treated patients in the 755-201-EB study were treated for non-wound itch.
INM-088 – Glaucoma Program
The Company continues to conduct IND-enabling preclinical testing for the development of a CBN-based eye drop formulation in glaucoma and has planned GLP toxicology studies in Q4 2023.
As part of the Company’s proprietary cannabinoid analog program, InMed continues to screen a library of new compounds across a spectrum of therapeutic applications, including other ocular indications such as Age-related Macular Degeneration (“AMD”) and other similar ‘back-of-the-eye’ diseases.
INM-900 – Neurodegenerative Diseases Program
Two cannabinoid analogs are being assessed in in vivo models of neurodegenerative diseases and the Company expects these studies to be completed and a candidate selected for further development in calendar 2Q 2023. Our research demonstrated the neuroprotective effects of specific cannabinoid analogs and their potential to improve neuronal function in in vitro testing.
InMed recently filed a patent application covering a range of cannabinoids demonstrating neuroprotection and enhanced neuronal function for the potential treatment of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others.
Publications
In March 2023, the Company announced the publication of a peer-reviewed scientific study entitled “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signaling pathway” in the International Journal of Molecular Sciences. The study, conducted in collaboration with Dr. Mauro Maccarrone at the Università degli Studi dell’Aquila, Italy, investigates the dermatological anti-inflammatory effects of certain rare cannabinoids. It is the second Company-sponsored study to demonstrate the anti-inflammatory effects of rare cannabinoids and their potential for the treatment of skin conditions such as atopic dermatitis, psoriasis, pruritus, and acne.
2
BayMedica Commercial Business
InMed’s BayMedica rare cannabinoids business, which serves the H&W sector, delivered its strongest revenue quarter since acquisition in late 2021. As a result of slower than anticipated product demand throughout 2022, in 2023, management took a conservative approach towards investment in inventory and new products while the sales and marketing function sought to develop commercial opportunities.
This approach has proven beneficial as, thus far in 2023, the H&W sector has experienced a significant increase in demand for rare cannabinoids, particularly CBC, where BayMedica has been well-positioned to be a key supplier to distributors and manufacturers. During the nine months ended March 31, 2023, revenues totaled more than $1.8 million, as sales surpassed $1 million in the third quarter alone, compared to $0.6 million for the nine months ended March 31, 2022.
While the medium- and long-term outlooks remain uncertain, sales and marketing efforts remain focused on products that have stable pricing, lower manufacturing costs, and where BayMedica holds a strong competitive position.
Financial and Operational Highlights:
For the nine months ended March 31, 2023, the Company recorded a net loss of $7.6 million, or $3.53 per share, compared with a net loss of $10.7 million, or $20.13 per share, for the nine months ended March 31, 2022.
Research and development and patents expenses decreased by $2.7 million for the nine months ended March 31, 2023 compared to the same period in 2022. The decrease was due to a combination of lower personnel expenses and high start-up costs associated with the multicenter Phase 2 clinical trial in our INM-755 program during fiscal 2022.
The Company incurred general and administrative expenses of $4.4 million for the nine months ended March 31, 2023 compared with $5.1 million for the nine months ended March 31, 2022. The decrease results primarily from a combination of changes including lower personnel expenses, insurance fees, investor relation expenses, accounting fees, legal fees and were offset by the inclusion of BayMedica operating results following its acquisition on October 13, 2021.
At March 31, 2023, the Company’s cash, cash equivalents and short-term investments were $9.6 million, which compares to $6.2 million at June 30, 2022. The increase in cash, cash equivalents and short-term investments during the nine months ended March 31, 2023, was primarily the result of both the September 13, 2022 and November 21, 2022 private placements partially offset by cash outflows from operating activities. With ongoing revenue from the BayMedica operations and depending on how we prioritize investment into our various development activities, InMed has a projected cash runway to the middle of fiscal 3Q 2024.
At March 31, 2023, the Company’s total issued and outstanding shares were 3,328,191. During the three and nine months ending March 31, 2023, the weighted average number of common shares was 3,328,191 and 2,156,283, which is used for the calculation of loss per share for the respective interim periods.
For the nine months ending March 31, 2023, InMed’s BayMedica subsidiary delivered $1.8 million in rare cannabinoid ingredient sales to distributors and manufacturers in the H&W sector, compared to $0.6 million in 2022, reflecting expanded marketing efforts and increased market demand. Gross profit margin was adversely affected by downward pricing pressure on certain products in the portfolio and a write-down of selected inventories to net realizable value of $0.6 million in the first quarter of 2023. We expect our overall gross profit and gross profit margins will improve over the coming quarters as sales and marketing efforts are focused on products with more stable pricing and lower manufacturing costs.
3
Table 1: Condensed Consolidated Interim Balance Sheets:
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS
As of March 31, 2023 (unaudited) and June 30, 2022
Expressed in U.S. Dollars
| March 31, | June 30, | |||||||
| 2023 | 2022 | |||||||
| $ | $ | |||||||
| ASSETS | ||||||||
| Current | ||||||||
| Cash and cash equivalents | 9,604,057 | 6,176,866 | ||||||
| Short-term investments | 43,055 | 44,804 | ||||||
| Accounts receivable, net | 170,299 | 88,027 | ||||||
| Inventories | 1,329,931 | 2,490,854 | ||||||
| Prepaids and other current assets | 695,203 | 797,225 | ||||||
| Total current assets | 11,842,545 | 9,597,776 | ||||||
| Non-Current | ||||||||
| Property, equipment and ROU assets, net | 753,241 | 904,252 | ||||||
| Intangible assets, net | 1,986,826 | 2,108,915 | ||||||
| Other assets | 147,489 | 176,637 | ||||||
| Total Assets | 14,730,101 | 12,787,580 | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current | ||||||||
| Accounts payable and accrued liabilities | 1,829,924 | 2,415,265 | ||||||
| Current portion of lease obligations | 423,574 | 404,276 | ||||||
| Deferred rent | 16,171 | - | ||||||
| Acquisition consideration payable | - | 500,000 | ||||||
| Total current liabilities | 2,269,669 | 3,319,541 | ||||||
| Non-current | ||||||||
| Lease obligations, net of current portion | 72,794 | 389,498 | ||||||
| Total Liabilities | 2,342,463 | 3,709,039 | ||||||
| Commitments and Contingencies (Note 14) | ||||||||
| Shareholders’ Equity | ||||||||
| Common shares, no par value, unlimited authorized shares: 3,328,191 (June 30, 2022 - 650,667) issued and outstanding | 77,620,252 | 70,718,461 | ||||||
| Additional paid-in capital | 35,700,635 | 31,684,098 | ||||||
| Accumulated deficit | (101,061,818 | ) | (93,452,587 | ) | ||||
| Accumulated other comprehensive income | 128,569 | 128,569 | ||||||
| Total Shareholders’ Equity | 12,387,638 | 9,078,541 | ||||||
| Total Liabilities and Shareholders’ Equity | 14,730,101 | 12,787,580 | ||||||
| Related Party Transactions (Note 16) | ||||||||
4
Table 2: Condensed Consolidated Interim Statements of Operations:
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (unaudited)
For the three and nine months ended March 31, 2023 and 2022
Expressed in U.S. Dollars
| Three Months Ended | Nine Months Ended | |||||||||||||||
| March 31 | March 31 | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| $ | $ | $ | $ | |||||||||||||
| Sales | 1,033,925 | 309,585 | 1,824,496 | 574,677 | ||||||||||||
| Cost of sales | 841,414 | 127,308 | 1,415,068 | 280,845 | ||||||||||||
| Inventory write-down | - | - | 576,772 | - | ||||||||||||
| Gross profit (loss) | 192,511 | 182,277 | (167,344 | ) | 293,832 | |||||||||||
| Operating Expenses | ||||||||||||||||
| Research and development and patents | 878,303 | 1,753,545 | 3,108,312 | 5,781,867 | ||||||||||||
| General and administrative | 1,412,727 | 1,915,017 | 4,438,083 | 5,124,670 | ||||||||||||
| Amortization and depreciation | 50,689 | 53,340 | 148,786 | 131,669 | ||||||||||||
| Total operating expenses | 2,341,719 | 3,721,902 | 7,695,181 | 11,038,206 | ||||||||||||
| Other Income (Expense) | ||||||||||||||||
| Interest and other income | 155,497 | 30,964 | 343,881 | 62,389 | ||||||||||||
| Foreign exchange gain (loss) | (2,733 | ) | 32,996 | (79,287 | ) | (48,109 | ) | |||||||||
| Loss before income taxes | (1,996,444 | ) | (3,475,665 | ) | (7,597,931 | ) | (10,730,094 | ) | ||||||||
| Tax expense | (1,500 | ) | - | (11,300 | ) | - | ||||||||||
| Net loss for the period | (1,997,944 | ) | (3,475,665 | ) | (7,609,231 | ) | (10,730,094 | ) | ||||||||
| Net loss per share for the period | ||||||||||||||||
| Basic and diluted | (0.60 | ) | (6.14 | ) | (3.53 | ) | (20.13 | ) | ||||||||
| Weighted average outstanding common shares | ||||||||||||||||
| Basic and diluted | 3,328,191 | 566,062 | 2,156,283 | 533,070 | ||||||||||||
5
Table 3: Condensed Consolidated Interim Statements of Cash Flows:
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited)
For the nine months ended March 31, 2023 and 2022
Expressed in U.S. Dollars
| 2023 | 2022 | |||||||
| $ | $ | |||||||
| Cash provided by (used in): | ||||||||
| Operating Activities | ||||||||
| Net loss | (7,609,231 | ) | (10,730,094 | ) | ||||
| Items not requiring cash: | ||||||||
| Amortization and depreciation | 148,786 | 131,669 | ||||||
| Share-based compensation | 237,675 | 521,006 | ||||||
| Amortization of right-of-use assets | 296,239 | 226,061 | ||||||
| Loss on disposal of assets | - | 11,355 | ||||||
| Change in value of short-term investments | (392 | ) | 46 | |||||
| Unrealized foreign exchange loss | 2,138 | 312 | ||||||
| Inventory write-down | 576,772 | - | ||||||
| Bad debts | 25,085 | - | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Inventories | 584,151 | (933,260 | ) | |||||
| Prepaids and other currents assets | 102,022 | (323,653 | ) | |||||
| Other non-current assets | 5,507 | 6,580 | ||||||
| Accounts receivable | (107,357 | ) | (22,535 | ) | ||||
| Accounts payable and accrued liabilities | (585,341 | ) | (195,125 | ) | ||||
| Deferred rent | 16,171 | 3,760 | ||||||
| Lease obligations | (317,490 | ) | (232,633 | ) | ||||
| Total cash used in operating activities | (6,625,265 | ) | (11,536,511 | ) | ||||
| Investing Activities | ||||||||
| Cash acquired from acquisition of BayMedica | - | 91,566 | ||||||
| Payment of acquisition consideration payable | (500,000 | ) | - | |||||
| Payment of deposit on equipment | (128,198 | ) | - | |||||
| Purchase of property and equipment | - | (39,108 | ) | |||||
| Total cash (used in) provided by investing activities | (628,198 | ) | 52,458 | |||||
| Financing Activities | ||||||||
| Shares issued for cash | 12,000,436 | 12,000,001 | ||||||
| Share issuance costs | (1,319,782 | ) | (1,294,247 | ) | ||||
| Repayment of debt | - | (261,514 | ) | |||||
| Settlement of debt upon acquisition of subsidiary | - | (425,000 | ) | |||||
| Total cash provided by financing activities | 10,680,654 | 10,019,240 | ||||||
| Increase (decrease) in cash during the period | 3,427,191 | (1,464,813 | ) | |||||
| Cash and cash equivalents beginning of the period | 6,176,866 | 7,363,126 | ||||||
| Cash and cash equivalents end of the period | 9,604,057 | 5,898,313 | ||||||
6
About InMed
InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: data read out expected in calendar 3Q 2023; being in a better position to evaluate our strategic opportunities for the INM-755 program; being increasingly excited about the data we are seeing in our preclinical ocular and neurodegenerative disease programs where we are researching proprietary cannabinoid analogs in the treatment of various indications; seeing a noticeable increase in awareness, understanding and adoption of rare cannabinoids in the H&W sector; leading companies expanding their product lines to include new formats and formulations using rare cannabinoids; being encouraged by two consecutive periods of significant quarter over quarter revenue growth; continuing to support growth in a fiscally prudent manner; the combination of a pharmaceutical drug development pipeline, together with a revenue generating commercial operation that will be contributing to extending our cash runway making InMed a unique company within the rare cannabinoid space; the net benefit from INM-755 cream will be evaluated within each patient and based on their clinical needs at baseline; advancing preclinical toxicology and having GLP studies planned for calendar 4Q 2023 in advance of human clinical trials planned for 2024; screening a library of new compounds across a spectrum of therapeutic applications including other ocular indications such as Age-related Macular Degeneration (“AMD”) and other similar ‘back-of-the-eye’ diseases; expecting in vivo studies to be completed and a candidate selected for further development in calendar 2Q 2023; the medium- and long-term outlook remains uncertain, sales and marketing efforts will remain focused on products that contribute high margins; having projected cash runway to the middle of fiscal 3Q 2024, depending on how we prioritize our investment into various development activities; expecting our overall gross profit and gross profit margins improving considerably over the coming quarters; all plans for our preclinical and clinical programs; being a global leader in the manufacturing and development and commercialization of rare cannabinoids and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.
Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
7